Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-23
    E.g., 2018-10-23

Archive Search

Pages

3412 items
12:00 AM, Jun 06, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg6/3 clsCymaBay Therapeutics Inc. (NASDAQ:CBAY)H.C. WainwrightEd ArceDowngradeNeutral (from buy)-19%$1.97 Arce also lowered his target to $2.25 from $6 after CymaBay reported mixed results from a Phase II trial...
12:00 AM, May 30, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/27 clsAlkermes plc (NASDAQ:ALKS)Evercore ISIUmer RaffatNewBuy7%$46.13 Raffat initiated coverage with a $59 target. He models a 65% probability of positive data from the Phase III FORWARD-5 trial of...
12:00 AM, May 23, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/20 clsArbutus Biopharma Corp. (NASDAQ:ABUS)Chardan CapitalMadhu KumarNewSell-6%$4.08 Kumar initiated coverage with a $3.25 target, saying competition to Arbutus' lead asset, ARB-1467, raises hurdles ahead of 2H16 catalysts. He...
12:00 AM, May 16, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/13 clsContraFect Corp. (NASDAQ:CFRX)Roth Capital PartnersJoseph PantginisDowngradeNeutral (from buy)-32%$2.20 Pantginis also lowered his target to $3.30 from $14. He predicts it will be 1.5-2 years before Phase II...
12:00 AM, May 09, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/6 clsAcadia Pharmaceuticals Inc. (NASDAQ:ACAD)Leerink PartnersPaul MatteisDowngradeMarket perform (from outperform)-14%$27.65 Matteis also lowered his target to $35 from $40. He remains "confident in the value proposition of pimavanserin"...
12:00 AM, May 02, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg4/29 clsDynavax Technologies Corp. (NASDAQ:DVAX)RBC Capital MarketsSimos SimeonidisDowngradeSector performer (from outperform)-26%$16.41 Simeonidis also lowered his target to $17 from $48 on continued concerns about Heplisav-B's safety. FDA extended...
12:00 AM, Apr 25, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg4/22 clsChiasma Inc. (NASDAQ:CHMA)CowenRitu BaralDowngradeMarket perform (from outperform)-62%$3.83 William BlairTim LugoDowngradeMarket perform (from outperform)Baral also removed her $32 target after FDA issued a complete response letter to an...
12:00 AM, Apr 11, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg4/8 clsBind Therapeutics Inc. (NASDAQ:BIND)CowenEric SchmidtDowngradeMarket perform (from outperform)-30%$1.57 Michael KingDowngradeMarket perform (from market outperform)Schmidt downgraded after Bind reported mixed results from two Phase II trials of BIND-014....
12:00 AM, Apr 04, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg1/1 clsAchaogen Inc. (NASDAQ:AKAO)CowenRitu BaralDowngradeMarket perform (from outperform)-9%$2.71 Baral downgraded on near-term cash flow concerns. She said Achaogen is counting on the extension of contracts with HHS's Biomedical...
12:00 AM, Mar 28, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg3/24 clsIronwood Pharmaceuticals Inc. (NASDAQ:IRWD)Goldman SachsJami RubinNewNeutral1%$10.39 Rubin initiated coverage with a $14 target. She said Ironwood is a commercial biopharma on the cusp of turning profitable in...

Pages